Abbott Glucose Monitor Recall Tied to 7 Deaths Raises Alarm — Advocates Urge Outreach to Immigrant Patients
Key Takeaways
- NBC News reports Abbott’s FreeStyle Libre 3 and Libre 3 Plus sensors are linked to at least seven deaths and more than 730 serious injuries worldwide; the company’s latest tally allegedly cites 860 injuries.
- An urgent warning covered about 3 million sensors in the U.S., with a manufacturing issue causing potentially false low glucose readings.
- Multiple lawsuits, including a wrongful death case and proposed class actions, question the scope of the recall and injury counts.
- Patient advocates say language-access gaps and insurance barriers could leave immigrant communities without timely, safe alternatives.
- There is no direct immigration-status impact: diabetes and use of glucose monitors do not make applicants inadmissible, and medical treatment is not penalized under current public-charge policy.
What Happened
NBC News reports that Abbott issued an urgent warning for approximately 3 million FreeStyle Libre 3 and Libre 3 Plus glucose sensors in the U.S., citing a manufacturing problem that can trigger falsely low readings. The issue has been linked to at least seven deaths and more than 730 serious injuries worldwide, with the company’s latest count allegedly reaching 860 injuries. One wrongful death lawsuit, filed by the son of a deceased patient in California, alleges the device readings were “catastrophically inaccurate,” prompting treatment decisions that preceded the patient’s death. The recall has intensified scrutiny of continuous glucose monitoring (CGM) technology relied upon by millions of people with diabetes.
Legal Fallout and Oversight
According to NBC News, the warning has already sparked at least three proposed class actions in the U.S., alongside the California wrongful death suit, and more individual claims are expected. While the report does not specify the U.S. Food and Drug Administration (FDA) recall classification, device recalls typically trigger reporting to FDA’s MedWatch program, which collects adverse event data. Lawyers and patient advocates are pressing Abbott and regulators for clearer guidance on which lots are affected and how quickly replacements can be provided, especially for patients who depend on real-time data to dose insulin safely.
Impact on Immigrants and Visa Applicants
The stakes may be higher in immigrant communities, where diabetes prevalence is significant among Latino, Black, and South Asian populations and where English-only notices can delay urgent safety actions. Insurance and eligibility hurdles—common for recent arrivals, mixed-status families, and undocumented people—can slow access to replacement sensors or clinical follow-up. Importantly, this recall has no direct immigration consequence: diabetes itself is not a ground of inadmissibility, and neither U.S. Citizenship and Immigration Services (USCIS) benefit adjudications nor consular medical exams penalize applicants for having diabetes or using a CGM. Under DHS’s current public-charge rule, receiving medical care is not counted against most applicants.
What This Means Right Now
For patients using FreeStyle Libre 3 or Libre 3 Plus sensors, the immediate issue is safety and continuity of care. It has been reported that Abbott notified U.S. consumers of the potential for false low readings; patients and caregivers should look for official communications from the manufacturer or their clinicians, including multilingual materials, and seek clarification on affected devices. Community health centers and legal aid groups note that product-safety remedies and legal protections apply regardless of immigration status, and adverse events can be reported to FDA MedWatch without sharing immigration-related information. As litigation and regulatory reviews unfold, clarity on the breadth of affected lots and the speed of replacements will determine how disruptive this recall is for people managing diabetes, including many immigrants balancing work, caregiving, and limited access to specialty care.
Source: Original Article